COTTAGE GROVE, Minn.--(BUSINESS WIRE)--LeafLine Labs, a physician-led organization built to cultivate, process and distribute medical cannabis in Minnesota, will open a second Care Center June 6 in St. Cloud. Its first, in Eagan, opened last year.
“Patient-centered care is at the heart of our mission, and we’re so proud to offer patients in central Minnesota a convenient and secure location to access this life-changing medicine,” said LeafLine Labs Chief Medical Officer Dr. Gary Starr. “We’ve seen a growing awareness of the potential and need for this safe and effective botanical remedy among Minnesota doctors and patients. This is an important next step in ensuring every Minnesotan child and adult enduring unnecessary suffering can receive the professional consultation and scientifically calibrated medicine they need to reclaim their lives.”
The new LeafLine Labs Care Center is located off Interstate 94 and Highways 15 and 23, at 141 33rd Avenue South, St. Cloud. It will be the first central Minnesota location for medical cannabis distribution, serving patients who have received certification from their health care practitioners of a qualifying condition and registered with the Minnesota Department of Health’s Office of Medical Cannabis.
Leafline Labs Care Centers are secure facilities, open by appointment, where highly qualified pharmacists and certified pharmacy technicians consult with patients to determine specific products, formulations and recommended dosages for each qualifying condition specified by the law. The new Care Center joins the original Care Center in Eagan and a production facility in Cottage Grove. Additional LeafLine Labs Care Centers will launch in Hibbing and Saint Paul in July.
An increase in patients seeking relief from medical cannabis is expected this summer, following the addition of “intractable pain” to the list of qualifying conditions by the Minnesota Department of Health July 1. Health care practitioners will begin certifying intractable pain patients on July 1, and patients will become eligible to receive medical cannabis on August 1.
“Prescription opiate overuse and abuse, worsening over the last decade, has resulted in a public health emergency — leaving tens of thousands Minnesotans chemically dependent, incarcerated or dead,” said Dr. Starr. “A growing body of evidence supports medical cannabis as a safer complementary or alternative treatment for chronic pain. We believe we have a moral duty to provide this safe, alternative treatment to every citizen who qualifies, and we are ready to do so under the parameters of Minnesota’s program, one of the nation’s most stringent and tightly-controlled.”
LeafLine Labs is one of only two Minnesota organizations licensed to cultivate, process and distribute medical cannabis as part of the state’s medical cannabis program, which launched in the summer of 2015. Focused on its mission to become the pre-eminent provider of the highest-quality medical cannabis treatment in the state, the company endeavors to improve the lives of Minnesotans suffering from medical conditions that potentially benefit from medical cannabis.